Discovery of a human monoclonal antibody that cross-neutralizes venom phospholipase A2s from three different snake genera

• Published in: Toxicon (Oxford) Vol. 234; p. 107307
• Main Authors: Sørensen, Christoffer V., Almeida, José R., Bohn, Markus-Frederik, Rivera-de-Torre, Esperanza, Schoffelen, Sanne, Voldborg, Bjørn G., Ljungars, Anne, Vaiyapuri, Sakthivel, Laustsen, Andreas H.
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.10.2023
• ISSN: 0041-0101; 1879-3150
• DOI: 10.1016/j.toxicon.2023.107307

Despite the considerable global impact of snakebite envenoming, available treatments remain suboptimal. Here, we report the discovery of a broadly-neutralizing human monoclonal antibody, using a phage display-based cross-panning strategy, capable of reducing the cytotoxic effects of venom phospholipase A2s from three different snake genera from different continents. This highlights the potential of utilizing monoclonal antibodies to develop more effective, safer, and globally accessible polyvalent antivenoms that can be widely used to treat snakebite envenoming. [Display omitted] •Improved and more accessible snakebite therapies are needed to reduce the negative effects caused by snakebite envenoming.•Recombinant antivenoms, composed of monoclonal antibodies have been hypothesized as a future snakebite envenoming therapy.•A novel human monoclonal IgG antibody shows broadly-neutralizing capabilities against myotoxicity from viperid snake venoms.•This broad neutralization affects venom from snakes belonging to three genera and originating from three continents.•While cross-reactive, the antibody retains selectivity to bind only a subset of the tested viperid venoms.